Adequacy of Immune Checkpoint Inhibitor–Associated Thyroid Function Monitoring After Therapy
Post-ICI thyroid dysfunction is frequent, with 11.6% of monitored patients being affected, and patients with abnormal TSH before ICI discontinuation and those who received treatment for 9 months or less may benefit from more stringent post-ICI surveillance.
Authors
- Arjan Gower (ORCID: https://orcid.org/0000-0002-3361-9286)
- Seung Jun Park
- Philippe Rochigneux (ORCID: https://orcid.org/0000-0001-7932-0530)
- Jackson P Lind-Lebuffe
- Elliot Kang (ORCID: https://orcid.org/0000-0002-0001-1186)
- Maria A. Velez (ORCID: https://orcid.org/0000-0001-5197-4719)
- Edward B. Garon (ORCID: https://orcid.org/0000-0001-7077-8801)
- Andy Han
- David A. Elashoff (ORCID: https://orcid.org/0000-0002-5865-8580)
- Aaron Elliott Lisberg (ORCID: https://orcid.org/0000-0003-3048-4352)
- Tristan Grogan (ORCID: https://orcid.org/0000-0001-9471-2938)
- Daniel Li (ORCID: https://orcid.org/0000-0003-4293-4509)
- Collin Shen
- Chester Andrew Thompson
Institutions
- University of California, Los Angeles (US)
- Institut Paoli-Calmettes (FR)
Publication Details
- Journal
- JCO Oncology Practice
- Published
- 2025-06-02
- DOI
- https://doi.org/10.1200/op-25-00027
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09